Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 3, 1999, Pages 267-272

  Chevreau, Christine ^a   Bui, Binh Nguyen ^b   Chevallier, Bernard ^c,d   Krakowski, Ivan ^g   Maugard, Christine ^e   Mihura, Jeanne ^a   Coindre, Jean Michel ^b   Gil, Bernard ^f   Cour Chabernaud, Véronique ^f  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d Centre A Vautrin   (France)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f SANOFI   (France)

^g Institut Claudius Regaud ^*

Author keywords

Hematopoietic growth factor; Intensified MAID regimen; Soft tissue sarcoma

Indexed keywords

DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; MUCOSA INFLAMMATION; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SOFT TISSUE SARCOMA;

EID: 0343133873     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199906000-00011     Document Type: Article

References (21)

1. Van Hoesel OGCM, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994;5:539-42.
2. Yang JC, Glatstein EJ, Rosenberg SA, et al. Sarcoma of soft tissue. In: de Vita Jr, Hellman S, Rosenberg SA, eds. Cancer principles and practice in oncology. 4th ed. Philadelphia: JB Lippincott, 1993:1436-88.
3. O'Bryan RM, Baker LH, Gottlieb JB, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940-8.
4. Antmann KH, Ryan L, Elias A, et al. Response ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-31.
5. Benjamin RS, Legha SS, Patel SR, et al. Single-agent ifosfamide studies in sarcomas of soft tissue and bone, the M.D. Anderson Hospital experience. Cancer Chemother Pharmacol 1993;31: S174-9.
6. Borden, Amato D, Enterline HT, et al. Randomized comparison of three adriamycin regimens for treatment of metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-50.
7. Edmonson JH, Ryan L, Blum RH, et al. Randomized comparison of doxorubicin alone vs ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
8. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-16.
9. Antman KS, Crowley J, Balcerzak SP, et al. An intergroup Phase III randomised study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue sarcomas. J Clin Oncol 1993;11:1276-85.
10. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988;319: 593-8.
11. Bui BN, Chevallier B, Chevreau C, et al. Efficacy of lenograstim on hematological tolerance to MAID chemotherapy in sarcoma patients and consequences on treatment dose intensity. J Clin Oncol 1995;13:2629-36.
12. Leyvras S, Bacchi M, Cerny T, et al. A phase I trial of intensification of ifosfamide and adriamycin with GM-CSF for the treatment of sarcomas [abstract]. Proc Am Soc Clin Oncol 1995;14: 1689.
13. Frustaci S, Buonadonna A, Favaro D, et al. Epirubicin, ifosfamide, and GM-CSF in soft tissue sarcoma patients: feasibility of EPI escalating dose and evaluation of correlated peripheral blood CFU-GM [abstract]. Proc Am Soc Clin Oncol 1993;12:1636.
14. Garnik MG, Weiss GR, Steele GD, et al. Clinical evaluation of long-term, continuous-infusion doxorubicin. Cancer Treat Rep 1983;67:133-42.
15. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft tissue sarcomas: a Southwest Oncology Group Study. J Natl Cancer Inst 1991;83:926-32.
16. Bronchud MH, Howell A, Crowther D, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989;60:121-5.
17. Seidman AD, Scher HI, Gabrilove JL, et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993; 11:408-14.
18. Seidman AD, Scher HI, Gabrilove JL, et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993; 11:408-14.
19. Palumbo R, Toma S. Feasibility and compliance of epirubicin plus ambulatory continuous infusion ifosfamide at escalating doses in advanced soft tissue sarcoma: a Phase I study. Eur J Cancer 1995;9:1552-3.
20. Steward WP, Verweil J, Somers R, et al. Granulocyte-macrophage colony stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993;11:15-21.
21. Turz T, Verweil J, Judson I, et al. Is high-dose chemotherapy of interest in advanced soft tissue sarcomas (ASTS)? An EORTC randomised phase III trial [Abstract 973]. Proc Am Soc Clin Oncol 1996;15:337.